JP6161705B2 - 新規キノリン置換化合物 - Google Patents
新規キノリン置換化合物 Download PDFInfo
- Publication number
- JP6161705B2 JP6161705B2 JP2015532903A JP2015532903A JP6161705B2 JP 6161705 B2 JP6161705 B2 JP 6161705B2 JP 2015532903 A JP2015532903 A JP 2015532903A JP 2015532903 A JP2015532903 A JP 2015532903A JP 6161705 B2 JP6161705 B2 JP 6161705B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- quinolin
- compound
- group
- methylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 BC(CC1C(C)(*)*)*CN(**)C1=N Chemical compound BC(CC1C(C)(*)*)*CN(**)C1=N 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013172746 | 2013-08-22 | ||
| JP2013172746 | 2013-08-22 | ||
| PCT/JP2014/071951 WO2015025936A1 (ja) | 2013-08-22 | 2014-08-22 | 新規キノリン置換化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2015025936A1 JPWO2015025936A1 (ja) | 2017-03-02 |
| JP6161705B2 true JP6161705B2 (ja) | 2017-07-12 |
Family
ID=52483707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532903A Active JP6161705B2 (ja) | 2013-08-22 | 2014-08-22 | 新規キノリン置換化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9650386B2 (https=) |
| EP (1) | EP3037424B1 (https=) |
| JP (1) | JP6161705B2 (https=) |
| KR (1) | KR101906688B1 (https=) |
| CN (1) | CN105683195B (https=) |
| AU (1) | AU2014309788B2 (https=) |
| BR (1) | BR112016003247B1 (https=) |
| CA (1) | CA2922077C (https=) |
| DK (1) | DK3037424T3 (https=) |
| ES (1) | ES2656712T3 (https=) |
| HU (1) | HUE034807T2 (https=) |
| MX (1) | MX370808B (https=) |
| MY (1) | MY182891A (https=) |
| NO (1) | NO3037424T3 (https=) |
| PH (1) | PH12016500225A1 (https=) |
| PL (1) | PL3037424T3 (https=) |
| PT (1) | PT3037424T (https=) |
| RU (1) | RU2689158C2 (https=) |
| SG (1) | SG11201600759XA (https=) |
| TW (1) | TWI603971B (https=) |
| WO (1) | WO2015025936A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016003247B1 (pt) * | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
| WO2018079310A1 (ja) * | 2016-10-31 | 2018-05-03 | 大鵬薬品工業株式会社 | エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤 |
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| FR3068971B1 (fr) * | 2017-07-12 | 2019-08-30 | Protneteomix | Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer |
| PL3677266T3 (pl) * | 2017-09-01 | 2024-07-01 | Taiho Pharmaceutical Co., Ltd. | Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21 |
| ES3033635T3 (en) * | 2018-12-28 | 2025-08-06 | Taiho Pharmaceutical Co Ltd | L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer |
| PT3943491T (pt) | 2019-03-19 | 2025-07-28 | Voronoi Inc | Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| CN115181104A (zh) * | 2019-09-29 | 2022-10-14 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| CN116096372B (zh) * | 2020-07-09 | 2024-09-03 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN117479943A (zh) | 2021-06-15 | 2024-01-30 | 基因泰克公司 | 组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途 |
| CN115707704B (zh) * | 2021-08-20 | 2024-09-13 | 广东医诺维申生物技术有限公司 | 氘代稠合三环类化合物及其组合物和用途 |
| JP2025538804A (ja) | 2022-12-08 | 2025-11-28 | アッシア ケミカル インダストリーズ リミテッド | ジパレルチニブの固体状態の形態及びそれを調製するための方法 |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| CN121285557A (zh) * | 2023-05-31 | 2026-01-06 | 大鹏药品工业株式会社 | 喹啉取代化合物的晶体 |
| WO2025141465A1 (en) | 2023-12-27 | 2025-07-03 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib hydrochloride and process for preparation thereof |
| WO2025167588A1 (zh) * | 2024-02-05 | 2025-08-14 | 苏州科睿思制药有限公司 | Zipalertinib的晶型及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) * | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| EP1871773A1 (en) | 2005-03-17 | 2008-01-02 | Novartis AG | N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| PT2452940E (pt) * | 2009-07-10 | 2015-02-27 | Taiho Pharmaceutical Co Ltd | Composto azabiciclo e seu sal |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| TW201309668A (zh) | 2011-01-07 | 2013-03-01 | Taiho Pharmaceutical Co Ltd | 新穎雙環式化合物或其鹽 |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| DK2722332T3 (en) * | 2012-02-23 | 2016-06-20 | Taiho Pharmaceutical Co Ltd | Quinolylpyrrolopyrimidylforbindelse with concentrated ring or salt thereof. |
| KR20150119401A (ko) * | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
| BR112016003247B1 (pt) * | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
-
2014
- 2014-08-22 BR BR112016003247-0A patent/BR112016003247B1/pt active IP Right Grant
- 2014-08-22 HU HUE14837210A patent/HUE034807T2/en unknown
- 2014-08-22 MX MX2016002125A patent/MX370808B/es active IP Right Grant
- 2014-08-22 ES ES14837210.5T patent/ES2656712T3/es active Active
- 2014-08-22 CN CN201480058192.XA patent/CN105683195B/zh active Active
- 2014-08-22 KR KR1020167007071A patent/KR101906688B1/ko active Active
- 2014-08-22 NO NO14837210A patent/NO3037424T3/no unknown
- 2014-08-22 SG SG11201600759XA patent/SG11201600759XA/en unknown
- 2014-08-22 EP EP14837210.5A patent/EP3037424B1/en active Active
- 2014-08-22 MY MYPI2016700465A patent/MY182891A/en unknown
- 2014-08-22 PL PL14837210T patent/PL3037424T3/pl unknown
- 2014-08-22 RU RU2016110096A patent/RU2689158C2/ru active
- 2014-08-22 JP JP2015532903A patent/JP6161705B2/ja active Active
- 2014-08-22 WO PCT/JP2014/071951 patent/WO2015025936A1/ja not_active Ceased
- 2014-08-22 DK DK14837210.5T patent/DK3037424T3/en active
- 2014-08-22 PT PT148372105T patent/PT3037424T/pt unknown
- 2014-08-22 TW TW103129036A patent/TWI603971B/zh active
- 2014-08-22 CA CA2922077A patent/CA2922077C/en active Active
- 2014-08-22 AU AU2014309788A patent/AU2014309788B2/en active Active
- 2014-08-22 US US14/911,093 patent/US9650386B2/en active Active
-
2016
- 2016-02-02 PH PH12016500225A patent/PH12016500225A1/en unknown
- 2016-12-19 US US15/382,883 patent/US9758526B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6161705B2 (ja) | 新規キノリン置換化合物 | |
| JP5557963B2 (ja) | キノリルピロロピリミジル縮合環化合物又はその塩 | |
| WO2013118817A1 (ja) | キノリルピロロピリミジン化合物又はその塩 | |
| JPWO2015022926A1 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
| RU2797117C2 (ru) | Новое хинолин-замещенное соединение | |
| HK1222393B (en) | Quinoline-substituted compound | |
| HK1202862B (en) | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170511 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170523 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170613 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6161705 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |